Dermatology

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.

Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.

Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.

Interim analysis suggest the JAK inhibitor may become a breakthrough treatment for chronic hand dermatitis—a condition currently without a marketed drug.

Post-hoc data from the phase 3 ADhere trial shows a lebrikizumab regimen may help patients with atopic dermatitis achieve skin clearance they could not with dupilumab.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

A Brazil cross-sectional analysis suggests chronic pruritus is even more common—and burdensome—in atopic dermatitis patients than previously believed.

A new qualitative study of adults with atopic dermatitis shows preference for skin clearance, reduced risk of severe adverse events and a less frequent dosage.

New data show the novel investigative drug from Amytrx was associated with 37% improvement in atopic dermatitis body surface area.

Updated analysis of more than a dozen clinical trials assessing monotherapy systemic treatment of atopic dermatitis shows upadacitinib's highly prevalent efficacy in clearing skin.

Boni Elewski, MD, and Benjamin Kaffenberger, MD, and Carly Elston, MD, reviews the symptoms that patients with generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), acrodermatitis continua of Hallopeau, Steven-Johnson syndrome (SJS), toxic epidermal necrolysis, linear IgA bullous dermatosis (LABD), and hidradenitis suppurativa typically present with in a dermatology clinic.

Recent data showed that a new HS-IGA tool for hidradenitis suppurativa addressed several concerns of prior tools but also maintained certain limitations.

Experts discuss some rare dermatological disorders that critical care physicians may see in the emergency room setting or dermatologists may see in their clinics along with the prevalence of these diseases.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

Mehmi described some of the major challenges to diagnosing mucosal melanoma in patients, as well as the small amount of data around treating the rare but dangerous condition.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

This interview featured Mehmi discussing a less well-known form of melanoma known as mucosal melanoma, a condition which he believes needs to be researched in greater depth.

Research indicates greater expertise in the non-invasive technique for diagnosis of basal cell carcinoma may be useful, although remote supervision of novice assessors by an expert may also help.

New data on US Medicare beneficiaries indicates that the head and neck region of the body was most commonly affected by squamous cell carcinomas compared to other areas.